Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements examine identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://luisj627bvx9.blog5star.com/profile